<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1592">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02444637</url>
  </required_header>
  <id_info>
    <org_study_id>RACE_1.0</org_study_id>
    <nct_id>NCT02444637</nct_id>
  </id_info>
  <brief_title>Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD</brief_title>
  <official_title>Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage Alzheimer's Disease Having Coexisting Small Vessel Cerebrovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Neuroscience Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Neuroscience Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rivastigmine, an acetylcholinesterase inhibitor which has been approved by FDA &amp; HSA, is&#xD;
      authorized for use in the treatment of mild to moderate dementia of the Alzheimer's type.&#xD;
&#xD;
      In this trial, the investigators will be studying the effectiveness of Rivastigmine in&#xD;
      subjects with AD and cerebrovascular disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">March 2019</completion_date>
  <primary_completion_date type="Actual">March 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Demonstrated Benefit in Global and Cognitive Measures</measure>
    <time_frame>2 Years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>2 Years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>CVA (Cerebrovascular Accident)</condition>
  <arm_group>
    <arm_group_label>Rivastigmine (Exelon) Patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For the first 4 weeks of the study, subjects will receive Rivastigmine patch 4.6mg/24 hours. Thereafter, subjects will receive Rivastigmine patch 9.5mg/24 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivastigmine</intervention_name>
    <arm_group_label>Rivastigmine (Exelon) Patch</arm_group_label>
    <other_name>Exelon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 50-85 years&#xD;
&#xD;
          -  Diagnosis of dementia of the Alzheimer's type according to the National Institute of&#xD;
             Ageing-Alzheimer's Association Criteriah&#xD;
&#xD;
          -  MRI brain (with T2 or FLAIR sequences) performed within a 12 month period from time of&#xD;
             recruitment demonstrating the presence of WMH of â‰¥2 on the Fazekas scale (Score range&#xD;
             of 0-3 wherein a score of 1 indicates mild WMH, 2 indicates moderate WMH and 3&#xD;
             indicates severe WMH).i&#xD;
&#xD;
          -  Clinical Dementia Rating score of 1-2j&#xD;
&#xD;
          -  Mini-Mental State Examination (MMSE) scores of 12-26 inclusivek&#xD;
&#xD;
          -  English or Mandarin speaking, literate participants&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe neurological, psychiatric or systemic disease which in the opinion of the&#xD;
             clinician could interfere with trial assessments&#xD;
&#xD;
          -  The use of any investigational drugs, new psychotropic or dopaminergic agents,&#xD;
             cholinesterase inhibitors or anti-cholinergic agents during the 4 weeks prior to&#xD;
             recruitment&#xD;
&#xD;
          -  Known skin allergy or previous allergic reaction to Rivastigmine patch&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Neuroscience Institute</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 28, 2015</study_first_submitted>
  <study_first_submitted_qc>May 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2015</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Neuroscience Institute</investigator_affiliation>
    <investigator_full_name>Dr Nagaendran Kandiah</investigator_full_name>
    <investigator_title>Senior Consultant, Department of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivastigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

